MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021
GAITHERSBURG, MD, September 02, 2021 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced that it will release financial results for the second quarter of 2021 after the U.S. market close on Monday, September 13th, 2021. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
Conference Call Details
Interested parties may access the live teleconference by dialing (844) 679-0933 for domestic callers or (918) 922-6914 for international callers, followed by Conference ID: 3199124. A live and archived webcast of the event will be available on the "Events" section of the MaxCyte website at https://investors.maxcyte.com/.
About MaxCyte
MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The Company's existing customer base ranges from large biopharmaceutical companies - including 20 of the top 25 pharmaceutical companies based on 2020 global revenue - to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 14 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.
MaxCyte Contacts:
|
MaxCyte Inc. Doug Doerfler, Chief Executive Officer Amanda Murphy, Chief Financial Officer
|
+1 301-944-1660 |
| Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden |
+44 (0)20 7886 2500 |
|
Joint Corporate Broker Numis Securities Limited James Black / Duncan Monteith / Matthew O'Dowd
|
+44 (0)20 7260 1000 |
| Joint Corporate Broker Stifel Nicolaus Europe Limited Healthcare Investment Banking Nicholas Moore / Ben Maddison / Samira Essebiyea Corporate Broking Nick Adams
|
+44 (0) 20 7710 7600
|
| UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh
|
+44 (0)203 709 5700 maxcyte@consilium-comms.com
|
| US IR Adviser Gilmartin Group David Deuchler, CFA |
+1 415-937-5400 ir@maxcyte.com
|
| US Media Relations Jamie Lacey-Moreira PressComm PR, LLC |
+1 410 299-3310 jamielacey@presscommpr.com
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
